Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Iannitto, Emilio;Ferrero, Simone;Bommier, Côme;Drandi, Daniela;Ferrante, Martina;Bouabdallah, Krimo;Carras, Sylvain;Gini, Guido;Camus, Vincent;Mancuso, Salvatrice;Marcheselli, Luigi;Ferrari, Angela;Merli, Michele;Tessoulin, Benoit;Stelitano, Caterina;Beldjord, Kheira;Roti, Giovanni;Jardin, Fabrice;Castagnari, Barbara;Palombi, Francesca;Baseggio, Lucile;Traverse-Glehen, Alexandra;Tripodo, Claudio;Liberati, Anna Marina;Parolini, Margherita;Usai, Sara;Patti, Caterina;Federico, Massimo;Musso, Maurizio;Ladetto, Marco

;Zucca, Emanuele;Thieblemont, Catherine

2025-01-01